Electra Therapeutics, Inc.

Overview

Compare with another stock.

• TickerETRA on Nasdaq¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersSouth San Francisco, California¹
• Incorporated inDE²
• Business address230 East Grand Avenue, Suite S-100, South San Francisco, Ca 94080²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Electra Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Electra Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerQuehuong (kathy) Dong Sep 18, 2026 to now³
• PresidentQuehuong (kathy) Dong Sep 18, 2026 to now³

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorQuehuong (Kathy) Dong, Pharm.D. named Oct 30, 2025¹⁰
• DirectorBeth Seidenberg, M.D. named Oct 30, 2025¹⁰
• DirectorCarl Gordon, Ph.D. named Oct 30, 2025¹⁰
• DirectorMatthew Fust named Oct 30, 2025¹⁰
• DirectorNancy Stagliano, Ph.D. named Oct 30, 2025¹⁰
• DirectorThomas Geninatti, Ph.D. named Oct 30, 2025¹⁰

Timeline

1. Sep 21, 20268-K Bylaws or fiscal year changed; Other events¹¹
2. Sep 18, 2026New chief executive Quehuong (kathy) Dong becomes CEO³

Filings

33 filings to the SEC since October 2021: 1 major events, 18 insider forms, 3 large holders, 1 private raises, 10 other. The latest 20:

1. Sep 28, 2026SCHEDULE 13G EDGAR
2. Sep 28, 2026SCHEDULE 13G EDGAR
3. Sep 25, 2026SCHEDULE 13D EDGAR
4. Sep 23, 20264 EDGAR
5. Sep 23, 20264 EDGAR
6. Sep 21, 20264 EDGAR
7. Sep 21, 20264 EDGAR
8. Sep 21, 20264 EDGAR
9. Sep 21, 20264 EDGAR
10. Sep 21, 2026S-8 EDGAR
11. Sep 21, 20268-K EDGAR
12. Sep 21, 20263 OWNERSHIP DOCUMENT EDGAR
13. Sep 18, 20263 EDGAR
14. Sep 18, 20263 EDGAR
15. Sep 18, 20263 EDGAR
16. Sep 18, 20263 EDGAR
17. Sep 18, 20263 EDGAR
18. Sep 18, 20263 EDGAR
19. Sep 18, 20263 EDGAR
20. Sep 18, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• 7. Cooperative Ua LspSCHEDULE 13G, 1 filing Sep 28, 2026¹²
• Redmile Group, LLCSCHEDULE 13G, 1 filing Sep 28, 2026¹³
• ORBIMED ADVISORS LLCSCHEDULE 13D, 1 filing Sep 25, 2026¹⁴

Money raised

Private offerings the company reported to the SEC on Form D.

1. Oct 15, 2025Raised $134.2 million in a private offering of equity Form D: $184.1 million offered in all Form D

SEC filer profile

How Electra Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARElectra Therapeutics, Inc.¹
• CIK0002088082
• Employer ID (EIN)83-2193635¹
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address230 East Grand Avenue, Suite S-100, South San Francisco, CA 94080¹
• Phone(888) 743-2290¹
• On EDGAR sinceOct 30, 2025¹
• Filings33 in all: 3 (12), 4 (6), SCHEDULE 13G (2), 424B4 (1), 8-A12B (1), 8-K (1), CERT (1), D (1)¹
  All 16 form types

  DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1), SCHEDULE 13D (1)

• Latest filingsLatest 8-K (8-K) Sep 21, 2026